KarJun24
reacted to
$Banks(LIST9025.MY$ Malaysia banking index jsut break higher high yesterday, signaled a potential further uptrend! The index move ahead of earning release, should I expect Malaysia banks to deliver outstanding results for last quarter?
$Banks(LIST9025.MY$ Daily Chart
The index was in a sideway to lower trend and marked its bottom in Jun 2023, followed by a strong rebound, all the way to more than 20% gains recently from its bottom. I would said 20% ...
$Banks(LIST9025.MY$ Daily Chart
The index was in a sideway to lower trend and marked its bottom in Jun 2023, followed by a strong rebound, all the way to more than 20% gains recently from its bottom. I would said 20% ...
48
KarJun24
liked
Is the market value of drugs for dementia expected to soar by 17.5 billion dollars in Genting?
(KUALA LUMPUR, 5th) The British pharmaceutical company TaurX, which holds about 20% of the shares in Genting (GENTING, 3182, main board consumer stock), will announce the results of the Phase 3 clinical trial of Alzheimer's disease (commonly known as dementia) drugs this Thursday (7th). Analysts believe that if the relevant drugs are approved, Genting's target price may soar to RM9.40.
Bank of Malaysia investment bank analysts pointed out that if the dementia drug HMTM developed were approved by the US and UK authorities, TaurX's market value could reach 15 billion US dollars (about RM70,850 million), and based on Genting's 20% shareholding, Genting's target price could soar from RM5.73 to RM9.40.
Based on a target price of RM9.40, Genting's market capitalization will reach RM36.4 billion, an increase of RM17.5 billion or 93% over today's market capitalization of RM18.9 billion.
The analyst said, “Currently, we have set the market value of TaurX at 1 billion US dollars (about RM7.09 billion). After a 60% discount on the valuation, Genting holds TaurX shares currently only account for 9 cents of our target price of RM5.73.”
However, he stressed that in the best case where HMTM is approved to launch the market and TaurX's market capitalization rises to $15 billion, Genting's target price can go up in one go...
(KUALA LUMPUR, 5th) The British pharmaceutical company TaurX, which holds about 20% of the shares in Genting (GENTING, 3182, main board consumer stock), will announce the results of the Phase 3 clinical trial of Alzheimer's disease (commonly known as dementia) drugs this Thursday (7th). Analysts believe that if the relevant drugs are approved, Genting's target price may soar to RM9.40.
Bank of Malaysia investment bank analysts pointed out that if the dementia drug HMTM developed were approved by the US and UK authorities, TaurX's market value could reach 15 billion US dollars (about RM70,850 million), and based on Genting's 20% shareholding, Genting's target price could soar from RM5.73 to RM9.40.
Based on a target price of RM9.40, Genting's market capitalization will reach RM36.4 billion, an increase of RM17.5 billion or 93% over today's market capitalization of RM18.9 billion.
The analyst said, “Currently, we have set the market value of TaurX at 1 billion US dollars (about RM7.09 billion). After a 60% discount on the valuation, Genting holds TaurX shares currently only account for 9 cents of our target price of RM5.73.”
However, he stressed that in the best case where HMTM is approved to launch the market and TaurX's market capitalization rises to $15 billion, Genting's target price can go up in one go...
Translated
10
![[empty]](https://static.moomoo.com/node_futunn_nnq/assets/images/folder.5c37692712.png)
![[error]](https://static.moomoo.com/node_futunn_nnq/assets/images/no-network.991ae8055c.png)
![[loading]](data:image/svg+xml;base64,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)